The search for the uremic toxin: The case for carbamoylation of amino acids and proteins

Wiener Klinische Wochenschrift

Volumn 110, Issue 15, 1998, Pages 521-530

  Kraus, Lorraine M ^a,b   Kraus Jr , Alfred P ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Carbamoyl amino acids; Carbamoyl proteins; Cyanate; Urea; Uremic toxin

Indexed keywords

AMINO ACID; CYANIC ACID; GLUCOSE; HOMOCITRULLINE; INSULIN; ISOCYANATE; LOW DENSITY LIPOPROTEIN; UREA; UREMIC TOXIN;

AMINO ACID METABOLISM; GLUCOSE TRANSPORT; HEMODIALYSIS; IMMUNOGENICITY; IMMUNOREACTIVITY; KIDNEY FUNCTION; LEUKOCYTE FUNCTION; PLASMA CLEARANCE; PROTEIN MALNUTRITION; PROTEIN SYNTHESIS INHIBITION; REVIEW; TRANSAMINATION; UREMIA;

AMINO ACIDS; BLOOD PROTEINS; CYANATES; GLOMERULAR FILTRATION RATE; HUMANS; TOXINS, BIOLOGICAL; UREA; UREMIA;

EID: 0032555523     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Wöhler F (1828) On the artificial formation of urea. Poggendorffs Ann Phys Chem 12: 253-256
2. Walker J, Hambly FJ (1895) Transformation of ammonium cyanate into urea. Trans Chem Soc 67: 746-768
3. Schutz F (1945) Pharmacological action of cyanic acid. Nature 155: 759
4. Schutz F (1946) Diuretic action of cyanate. J Physiol 105: 17
5. Birch KM, Schutz F (1946) Actions of cyanate. Br J Pharmacol 1: 186-193
6. Dirnhuber P, Schutz F (1948) The isomeric transformation of urea into ammonium cyanate in aqueous solution. Biochem J 42: 628-632
7. Holtham SB, Schutz F (1949) The effect of cyanate on the stability of proteins. Biochim Biophys Acta 3: 65-81
8. Stark GR, Stein WH, Moore S (1960) Reactions of cyanate present in aqueous urea with amino acids and proteins. J Biol Chem 235: 3177-3181
9. 2-terminal residues in proteins. J Biol Chem 238: 214-226
10. Stark GR (1965) Reactions of cyanate with functional groups of proteins III. Reactions with amino and carboxyl groups. Biochemistry 4: 1030-1036
11. Stark GR (1967) Modification of proteins with cyanate. In: Hirs CHW (ed) Methods in enzymology, vol. 11. Academic Press, New York, pp 590-594
12. 2-terminal cysteine and cystine in proteins. J Biol Chem 239: 1411-1414
13. Smyth DG (1967) Carbamylation of amino and tyrosine hydroxyl groups: separation of an inhibitor of oxytocin with no intrinsic activity on the isolated uterus. J Biol Chem 242: 1579-1591
14. Cerami A, Manning JM (1971) Potassium cyanate as an inhibitor of the sickling of erythrocytes in vivo. Proc Natl Acad Sci USA 68: 1180-1183
15. Gillette PN, Manning JM, Cerami A (1971) Increased survival of sickle-cell erythrocytes after treatment in vitro with sodium cyanate. Proc Natl Acad Sci USA 68: 2791-2793
16. Cerami A (1972) Cyanate as an inhibitor of red-cell sickling. N Engl J Med 287: 807-812
17. Cerami A, Manning JM, Gillette PN, De Furia F, Miller D, Graziano JH, Peterson CM (1973) Effect of cyanate on red blood cell sickling. Fed Proc 32: 1668-1672
18. Cerami A, Allen TA, Graziano JH, De Furia FG, Manning JM, Gillette PN (1973) Pharmacology of cyanate. I. General effects on experimental animals. J Pharmacol Exp Ther 185: 653-666
19. Graziano JH, Thornton YS, Leong JK, Cerami A (1973) Pharmacology of cyanate. I Effects on the endocrine system. J Pharmacol Exp Ther 185:667-675
20. Leong JK, Grady RW, Herbert J, Graziano JH, Cerami A, Judge M, Quartermain D (1974) Pharmacology of cyanate. III. Effects on the central nervous system. J Pharmacol Exp Ther 191: 60-67
21. Manning JM, Lee CK, Cerami A, Gillette PN (1973) Gas Chromatographic determination of the carbamoylation of hemoglobin S by cyanate. J Lab Clin Med 81: 941-945
22. Nigen AM, Peterson CM, Gillette PN, Manning JM (1974) Determination of the blood concentrations of cyanate after intravenous administration to patients with sickle cell disease. J Lab Clin Med 83: 139-146
23. Nigen AM, Manning JM, Peterson CM, White JM (1975) Bioavilability of sodium cyanate in patients with sickle cell disease and the lack of inhibition in vitro of globin synthesis at in vivo concentrations of cyanate. J Pharmacol Exp Ther 195:333-339
24. Gillette PN, Peterson CM, Lu YS, Cerami A (1974) Sodium cyanate as a potential treatment for sickle-cell disease. N Engl J Med 290: 654-660
25. Peterson CM, Tsairis P, Ohnishi A, Lu YS, Grady R, Cerami A, Dyck PJ (1974) Sodium cyanate induced polyneuropathy in patients with sickle-cell disease. Ann Intern Med 81: 152-158
26. Nicholson DH, Harkness DR, Benson WE, Peterson CM (1976) Cyanate-induced cataracts in patients with sickle-cell hemoglobinopathies. Arch Ophthalmol 94: 927-930
27. Kraus LM, Miyamura S, Pecha BR, Kraus AP Jr (1991) Carbamoylation of hemoglobin in uremic patients determined by antibody specific for homocitrulline (carbamoylated ∈-N-Lysine). Mol Immunol 28: 459-463
28. Moore S, Stein WH (1951) Chromatography of amino acids on sulfonated polystyrene resins. J Biol Chem 192:663-681
29. Heinrikson RL, Meredith SC (1984) Amino acid analysis by reverse-phase high-performance liquid Chromatography: precolumn derivatization with phenylisothiocyanate. Anal Biochem 136: 65-74
30. Jarrett HW, Cooksy KD, Ellis B, Anderson JM (1986) The separation of ophthalaldehyde derivatives of amino acids by reverse-phase chromatography on octylsilica columns. Anal Biochem 153: 189-198
31. Kraus LM, Jefferson WE, Kraus AP Jr (1986) In vivo generation of carbamoylated amino acids measured by RPHPLC. Fed Proc 45: 1614A
32. Kraus LM, Kraus AP Jr (1991) Tyrosine and N-carbamoyl-tyrosine in end stage renal disease during continuous ambulatory peritoneal dialysis. J Lab Clin Med 118: 555-562
33. Kopple JD, Blumenkrantz MJ, Jones MR, Moran JK, Coburn JW (1982) Plasma amino acid levels and amino acid losses during continuous ambulatory peritoneal dialysis. Am J Clin Nutr 36: 395-402
34. Lindholm B, Alvestrand A, Fürst P, Bergström J (1989) Plasma and muscle free amino acids during continuous ambulatory peritoneal dialysis. Kidney Int 35: 1219-1226
35. Druml W, Lochs H, Roth E, Hübl W, Balcke P, Lenz K (1991) Utilization of tyrosine dipeptides and acetyltyrosine in normal and uremic humans. Am J Physiol 160: E280-E285
36. Blumenkrantz MJ, Gahl GM, Kopple JD, Kamdar AV, Jones MR, Kessel M, et al (1981) Protein losses during peritoneal dialysis. Kidney Int 19: 593-602
37. Giordano C, DeSanto NG, Capodicasa G, Di Leo VA, Di Serafino A, Cirillo D, et al (1980) Amino acid losses during CAPD. Clin Nephrol 14: 230-232
38. Berlyne GM, Lee HA, Giordano C, de Pascale C, Esposito R (1967) Amino acid loss in peritoneal dialysis. Lancet ii: 1339-1341
39. Gjessing J (1968) Addition of amino acids to peritoneal dialysis fluid. Lancet ii: 812
40. Alvestrand A, Bergström J, Fürst P, Germanis G. Widstam U (1978) Effect of essential amino acid supplementation on muscle and plasma free amino acids in chronic uremia. Kidney Int 14: 323-332
41. Bergström J, Fürst P, Noree LO, Vinnars E (1978) Intracellular free amino acids in muscle tissue of patients with chronic uraemia: effect of peritoneal dialysis and infusion of essential amino acids. Clin Sci Mol Med 54: 51-60
42. Garibotto G, Deferrari G, Robaudo C, Saffioti S, Salvido G, Paoletti E, et al (1987) Effect of amino acid ingestion on blood amino acid profile in patients with chronic renal failure. Am J Clin Nutr 46: 949-954
43. Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F (1989) CAPD with an amino acid dialysis solution: a long-term, cross-over study. Kidney Int 35: 1189-1194
44. Mitch WE, Walser M, Steinman TI, Hill S, Zeger S, Tungsanga K (1984) The effect of ketoacid-amino acid supplement to a restricted diet on the progression of chronic renal failure. N Engl J Med 311: 623-629
45. Kopple JD, Bernard D, Messana J, Swartz R, Bergstrom J, Lindholm B, et al (1995) Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47: 1148-1157
46. Kraus LM, Jones MR, Kraus AP Jr (1998) Essential carbamoyl-amino acids formed in vivo in patients with end-stage renal disease managed by continuous ambulatory peritoneal dialysis: isolation, identification, and quantitation. J Lab Clin Med 131: 425-431
47. Kraus LM, Stephens MC (1987) Protein synthesis in the presence of carbamoyl-amino acids. FASEB J 2: 927A
48. Kraus LM, Kraus AP Jr (1988) Hemoglobin biosynthesis in the presence of carbamoyl-amino acids. Proceedings of the XXII Congress of the International Society of Hematology. August 28-September 2, 1988, Milan, Italy p 192A
49. Kraus LM, Nishimoto SK, Kraus AP Jr (1992) Carbamoylation in chronic renal failure: in vitro inhibition of protein synthesis by carbamoyl-amino acids. J Am Soc Nephrol 3: 743 A
50. Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335: 1897-1905
51. Fluckiger R, Harmon W, Meier W, Loo S, Gabbay KH (1981) Hemoglobin carbamylation in uremia. N Engl J Med 304: 823-827
52. Kraus, AP Jr, Soni P, Stephens MC, Kraus LM (1983) Carbamoylated hemoglobin in uremia: continuous ambulatory peritoneal dialysis (CAPD) versus hemodialysis. Blood 62: 47A
53. Smith WGJ, Holden M, Benton M, Brown CB (1988) Carbamylated haemoglobin in chronic renal failure. Clin Chim Acta 178: 297-304
54. Kwan JTC, Carr EC, Bending MR, Barron JL (1990) Determination of carbamylated hemoglobin by high-performance liquid chromatography. Clin Chem 36: 607-610
55. Kwan JTC, Carr EC, Neal AD, Burdon J, Raftery MJ, Marsh FP, Barron JL, Bending MR (1991) Carbamylated haemoglobin, urea kinetic modelling and adequacy of dialysis in haemodialysis patients. Nephrol Dial Transplant 6: 38-43
56. Davenport A, Jones SR, Goel S, Astley JP, Hartog M (1993) Differentiation of acute from chronic renal impairment by detection of carbamylated haemoglobin. Lancet 341: 1614-1617
57. Stim J, Shaykh M, Anwar F, Ansari A, Arruda JAL, Dunea G (1995) Factors determining hemoglobin carbamylation in renal failure. Kidney Int 48: 1605-1610
58. Davenport A, Jones S, Goel S, Astley JP, Feest TG (1996) Carbamylated hemoglobin: a potential marker for the adequacy of hemodialysis therapy in end-stage renal failure. Kidney Int 50: 1344-1351
59. Balon CM, Draisey TF, Thibert RJ (1998) Carbamylated hemoglobin and carbamylated plasma protein in hemodialyzed patients. Kidney Int 53: 488-495
60. Eschbach JW (1989) The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148
61. Trepanier DJ, Thibert RJ, Draisey TF, Caines PS (1996) Carbamylation of erythrocyte membrane proteins: an in vitro and in vivo study. Clin Biochem 29: 347-355
62. Alvestrand A, Wahren J, Smith D, De Fronzo RA (1984) Insulin-mediated potassium uptake is normal in uremic and healthy subjects. Am J Physiol 246: E174-E180
63. Kraus LM, Traxinger R (1994) N-carbamoyl-L-asparagine inhibits insulin sensitive glucose uptake in rat adipocytes. The 7th International Congress on Nutrition and Metabolism in Renal Disease, Stockholm, Sweden, pp 194-195A
64. Kraus LM, Florendo KN, Kraus AP Jr (1996) Effects of glycosylation on carbamoyl-amino acids in diabetic-ESRD patients. The 8th International Congress of Nutrition and Metabolism in Renal Disease, Naples, Italy, p18A
65. Pagani R, Ponticelli F, Terzuoli L, Leoncini R, Marinello E (1991) The inhibition of rat liver threonine dehydratase by carbamoyl-phosphate The formation of carbamoylpyridoxal 5′-phosphate. Biochim Biophys Acta 1077: 233-240
66. Jung K, Mildner D, Jacob B, Scholz D, Precht K (1981) On the pyridoxal 5′-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing haemodialysis and with kidney transplants. Clin Chim Acta 115 :105-110
67. Hartmeier GM, Sawhney AK, Yang BI (1983) Inhibition of coenzyme activation of aspartate aminotransferase. Biochem Biophys Res Commun 112: 629-637
68. Van Lente F, McHugh A, Pippenger CE (1986) Carbamylation of apo-aspartate aminotransferase: a possible mechanism for enzyme mactivation in uremic patients. Clin Chem 32: 2107-2108
69. Roxborough HE, Millar CA, McEneny J, Young IS (1995) Carbamylation inhibits the ferroxidase activity of caeruloplasmin. Biochem Biophys Res Commun 214: 1073-1078
70. Cohen G, Rudnicki M, Hörl WH (1998) Isolation of modified ubiquitin as a neutrophil chemotaxis, inhibitor from uremic patients. J Am Soc Nephrol 9: 451-456
71. Kraus LM, Mynatt RG, Kraus AP Jr (1997) Carbamoyl-amino acid daily losses in dialysate and urine, during CAPD. J Am Soc Nephrol 8: 286A
72. Kraus LM, Kraus AP Jr (1996) Uremic status assessed by carbamoylated ∈-amino-lysine (∈-N-C-Lys) in plasma. J Am Soc Nephrol 7: 1517A
73. Kraus LM, Elberger AJ, Handorf CR, Pabst MJ, Kraus AP, Jr. (1994) Urea-derived cyanate forms ∈-amino-carbamoyl-lysine (homocitrulline) in leukocyte proteins in patients with end-stage renal disease on peritoneal dialysis. J Lab Clin Med 123: 882-891
74. Blobel G (1985) Gene gating: a hypothesis. Proc Natl Acad Sci USA 82: 8527-8529
75. Kraus LM, Gaber L, Handorf CR, Kraus AP Jr (1993) In situ carbamoylation of kidney proteins by urea-derived cyanate forming homocitrulline (∈-amino-carbamoyl-lysine) identified by anti-homocitrulline antibody. J Am Soc Nephrol 4: 252A
76. Turck J, Pollock AS, Lee LK, Marti H-P, Lovett DH (1996) Matrix- metalloproteinase 2 (gelatinase A) regulates glomerular cell proliferation and differentiation. J Biol Chem 271: 15074-15083
77. Oimomi M, Ishikawa K, Kawasaki T, Kubota S, Yoshimuria Y, Baba S (1983) Plasma carbamoylated protein in renal failure. N Engl J Med 308: 655-656
78. Kraus, AP Jr, Stephens MS, Kraus LM (1985) Carbamoylation of plasma proteins in CAPD and HD. Kidney Int 27: 181A
79. Bachmann K, Valentovic M, Shapiro R (1980) A possible role for cyanate in the albumin binding defect of uremia. Biochem Pharm 29: 1598-1601
80. Bachmann K, Valentovic M, Shapiro R (1981) Contribution of cyanate to the albumin binding defect of uremia. Biochem Pharm 30: 1059-1063
81. Erill S, Calvo R, Carlos R (1980) Plasma protein carbamylation and decreased acidic drug protein binding in uremia. Clin Pharm Ther 27: 612-618
82. Aguirre C, Calvo R, Rodriguez-Sasiain JM (1993) Unchanged protein binding of penbutolol in renal isufficiency: a possible role of carbamylation. Internat J Clin Pharm Ther Toxicol 31: 31-34
83. Crist RD, Parellada PP (1976) Carbamyl phosphate-cyanate and CNS toxicity. in: Grisolia S, Baguena R, Mayor F (eds) The urea cycle. John Wiley & Sons, New York, pp491-499
84. Maddock AL, Westenfelder C (1996) Urea induces heat shock response in human neuroblastoma cells. J Am Soc Nephrol 7:275-282
85. Carreras J, Chabas A, Diederich D (1976) Physiological and clinical implications of protein carbamylation. In: Grisolia S, Baguena R, Mayor F (eds) The urea cycle. John Wiley & Sons, New York, pp 501-548
86. Shaw DC, Stein WH, Moore S (1964) Inactivation of chymotrypsin by cyanate. J Biol Chem 239: PC671-PC673
87. Veronese FM, Piszkiewicz D, Smith EL (1972) Inactivation of bovine glutamate dehydrogenase by carbamoyl phosphate and cyanate. J Biol Chem 247: 754-759
88. Bell WR, Charache S (1974) Effect of cyanate on clottability of fibrinogen. J Lab Clin Med 83: 790-796
89. Oimomi M, Hatanaka H, Yoshimura Y, Yokono K, Baba S, Taketomi Y (1987) Carbamylation of insulin and its biological activity. Nephron 46: 63-66
90. Chen CC, Grossberg AL, Pressman D (1962) Effect of cyanate on several anti-haptin antibodies: evidence for the presence of an amino group in the site of anti-p-azobenzenearsonate antibody. Biochemistry 1: 1025-1030
91. Steinbrecher UP, Fisher M, Witztum JL, Curtiss, LK (1984) Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J Lipid Res 25: 1109-1116
92. Weisgraber KH, Innerarity TL, Mahley RW (1978) Role of the lysine residues of plasma lipoproteins in high affinity binding to cell suface receptors on human fibroblasts. J Biol Chem 253: 9053-9062
93. Horkko S, Savolainen MJ, Kerviven K, Kesaniemi YA (1992) Carbamoylation induced alterations in low-density lipoprotein metabolism. Kidney Int 41: 1175-1181
94. Horkko S, Huttunen K, Kervinen K, Kesaniemi YA (1994) Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 24: 105-113
95. Loughrey CM, Jackson PC, McGinty A, McEneny J, Young IS (1994) Cytotoxicity of carbamylated LDL cholesterol to human fibroblasts. J Am Soc Nephrol 5: 496A
96. Smith WGJ, Holden M, Benton M, Brown CD (1989) Glycosylated and carbamoylated haemoglobin in uraemia. Nephrol Dial Transplant 4: 96-100
97. Trepanier DJ, Thibert RJ (1996) Carbamylation of erythrocyte membrane aminophospholipids: an in vitro and in vivo study. Clin Biochem 29: 333-345